Technology Transfer 101: How Academic Discoveries Become Real Medicines - a blogpost by ESR9 Bohdana Sokolova

Last week, I found myself surrounded by nearly 100 early-career researchers at a doctoral conference we organized with the topic "beyond the defense" in mind. The energy was infectious—brilliant minds presenting their research, from novel cancer therapeutics to diagnostic tools. But as the day progressed, I noticed a pattern in the conversations during coffee breaks. The most common question wasn't about methodologies or results—it was "What comes next?"

As PhD students, we spend years mastering the art of discovery, meticulously designing experiments and pushing the boundaries of human knowledge. But rarely do we learn what happens when our discoveries need to become real-world solutions that actually help patients. That gap between the bench and bedside? It's where most academic breakthroughs go to die.

This question hit particularly close to home because I've been asking it myself. As I navigate my own PhD journey in drug discovery through the Marie Curie ALLODD network, I've become increasingly curious about the innovation ecosystem—the bridge between academic labs and patient impact. So when an opportunity arose to explore medical technology valuation through a unique collaboration between Karolinska Institute and the University of Minnesota's Carlson School of Management, I jumped at it. What I discovered completely changed how I think about innovation.

When Scientists Meet MBAs: A Meeting of Minds
The course format was brilliantly simple: put PhD students from KI together with MBA students from Carlson, give them real medical technology assessment challenges, and watch what happens when two completely different worldviews collide.
On one side, you had us—the scientists. We spoke in terms of mechanism of action, clinical endpoints, and regulatory pathways. We could dissect a drug's molecular target with surgical precision but would get lost when asked about market penetration strategies. On the other side were the MBA students, fluent in financial modeling, competitive analysis, and go-to-market strategies, but who might struggle to distinguish between a small molecule and a biologic.
The magic happened in the collision.

Working through technology valuation cases, I watched as my MBA teammates approached our drug discovery research with questions I'd never considered: "What's the total addressable market? Who are the key competitors? What's your intellectual property position? How does reimbursement work in different healthcare systems?" Meanwhile, they were fascinated by our ability to assess technical risk, understand regulatory science, and evaluate whether a proposed mechanism was actually feasible.

One particularly eye-opening moment came when we were evaluating a novel diagnostic technology. I immediately dove into the technical specifications—sensitivity, specificity, and analytical validation requirements. My MBA partner looked at the same technology and asked, "But who's going to pay for this? How does it fit into existing clinical workflows? What's the cost per test?" Both perspectives were essential; neither alone would have led to an accurate assessment.

The course taught us frameworks for technology valuation that combined both lenses: discounted cash flow analysis that accounted for technical risk, real options valuation that considered both scientific and commercial uncertainties, and market assessment that factored in regulatory timelines. But more importantly, it showed us how innovation actually happens—not in isolation, but through collaboration between complementary skill sets.

The Hidden Reality of Innovation
This experience illuminated something crucial about the technology transfer ecosystem that isn't taught in graduate school: successful innovation requires translation, not just discovery.

Most academic discoveries never make it to patients not because the science is bad, but because there's a fundamental communication gap between the worlds of research and business. Scientists are trained to think about statistical significance and mechanistic understanding. Investors think about market size and return on investment. Regulators think about safety and efficacy. Clinicians think about workflow integration and patient outcomes.

These aren't competing priorities—they're all essential pieces of the same puzzle. But too often, they exist in silos.

Universities have technology transfer offices designed to bridge this gap, but the reality is more complex. A typical tech transfer process involves invention disclosure, patent application, market assessment, licensing negotiations, and ongoing relationship management. Each step requires different expertise and different ways of thinking about the same underlying science.

The most successful examples of academic technology transfer happen when teams understand multiple perspectives from the start. Think about the development of CAR-T cell therapy—it required not just immunology expertise, but also manufacturing know-how, regulatory strategy, and business model innovation. The scientists who founded companies like Kite Pharma didn't just make scientific breakthroughs; they learned to speak multiple languages.

The Skills They Don't Teach in Graduate School
Reflecting on the KI-Carlson experience, I realized how many crucial skills are missing from traditional PhD training:

Market Awareness: Understanding not just whether your research could work, but whether anyone would want it and pay for it. This means learning to assess competitive landscapes, understand healthcare economics, and think about adoption barriers.

Financial Literacy: Being able to build basic financial models, understand investment criteria, and communicate value propositions in business terms. You don't need an MBA, but you need to understand how investors think.

Regulatory Intelligence: Knowing how your research fits into approval pathways, what evidence standards apply, and how regulatory requirements shape development strategies. This is especially crucial in drug discovery, where regulatory risk can make or break a program.

Cross-Functional Communication: The ability to translate complex scientific concepts for non-scientific audiences without dumbing them down. This isn't just about making pretty slides—it's about understanding what different stakeholders care about and framing your work accordingly.

Partnership Building: Most innovations succeed through collaboration, not heroic individual efforts. Learning to identify complementary expertise and build productive working relationships across disciplines is essential.

Your Research, Your Future: Practical Next Steps
So what does this mean for you as a PhD student? Start by honestly evaluating your research's innovation potential:

• Assess the landscape: Who else is working on similar problems? What approaches have failed and why? Where are the white spaces?
• Understand your value proposition: What makes your approach unique? What problems does it solve that current solutions don't address?
• Map the pathway: What would it take to get from your current research to a real-world application? What are the key technical, regulatory, and commercial hurdles?
• Build your network: Connect with your university's technology transfer office. Attend industry conferences. Find mentors who've made the transition from academia to industry or entrepreneurship.

Consider seeking out experiences like the KI-Carlson program. Many universities offer innovation and entrepreneurship courses designed for scientists. Organizations like AAAS, NIH, and various industry associations provide workshops on technology transfer and commercialization.

Most importantly, start thinking about innovation early in your PhD, not as an afterthought. The decisions you make about research direction, intellectual property, and collaboration can significantly impact the ultimate real-world potential of your work.

Bridging Two Worlds
That room of 100 eager PhD students represents incredible untapped potential—not just for scientific discovery, but for innovation that changes lives. Each person there is working on research that could potentially help patients, improve healthcare, or solve pressing global challenges. But potential alone isn't enough.

The KI-Carlson collaboration taught me that innovation isn't just about having great ideas; it's about building bridges between different worlds of expertise. It's about learning to see your research through multiple lenses and finding collaborators who complement your strengths.

Understanding the path from bench to bedside isn't just about career options—though it certainly opens doors to industry, consulting, venture capital, and entrepreneurship. It's about maximizing the impact of all those late nights in the lab, all those failed experiments that taught you something new, and all that passion for discovery that got you into science in the first place.
​
Because at the end of the day, the goal isn't just to publish papers or graduate with a PhD. It's to contribute to human knowledge in ways that make the world a little bit better. And sometimes, that requires learning to speak more than one language.